Clinical Laserthermia Systems AB (publ) announced its participation in a national French study together with Urolib (urological team of the Medical Center Chateau Galland (MCCG)) in Besançon, France, and that the first patient was safely treated with CLS TRANBERG® Thermal Therapy system for laser ablation of prostate cancer. The multicenter study, named the IRMPROFT Study, aims to investigate the ?Performance of Prostate MRI and targeted biopsy to detect residual Prostate cancer following focal therapy?. Various focal therapy technologies are being used at the different study sites, and Urolib in Besançon has selected the CE-marked and FDA 510(k) cleared CLS TRANBERG® Thermal Therapy system as its focal therapy of choice.

According to the agreement, Urolib purchases the accessories and disposables needed for treatment and CLS provides technical and clinical support.